Drugs / Inosine pranobex
Inosine pranobex
Trials 8 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04360122 Comparator | May → Nov 2020 | COVID-19 | Ain Shams University | Unknown | No outcome recorded |
| Phase 3 | NCT04383717 Comparator | May → Aug 2020 | respiratory tract infectious disorder | Cairo University | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Inosine pranobex | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00002295 ↗ |
| Known as | Isoprinosine | “The objective is to determine the effect of Isoprinosine (inosine pranobex) in homosexual male patients with AIDS related complex (ARC) in delaying the onset of AIDS.” NCT00002060 ↗ |
| Known as | Metisoprinol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03883334 ↗ |
| Route | Oral | “All patients take INPX capsules 4 times a day and RBV capsules 2 or 3 times a day.” NCT00000699 ↗ |